Should patients with mitral stenosis and atrial fibrillation receive combined antithrombotic therapy?
Vittorio Pengo
Correspondence Department of Cardiologic, Thoracic and Vascular Sciences, University of Padua School of Medicine, Padua 35128, Italy
Email vittorio.pengo@unipd.it
This article has no abstract so we have provided the first paragraph of the full text.
Oral anticoagulation is the treatment of choice for the prevention of systemic thromboembolism in patients with mitral stenosis and associated atrial fibrillation or previous thromboembolism. This conclusion is not the consequence of results obtained in randomized controlled trials but comes from solid evidence drawn from uncontrolled clinical studies. The usefulness of anticoagulation in this clinical setting is reinforced by its benefit in patients with atrial fibrillation, and by the fact that thrombi that are formed as a consequence of impaired blood influx into the left ventricle are rich in fibrin.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
